Ibritumomab tiuxetan is an immunoconjugate consisting of the murine IgG1κ anti-CD20 monoclonal antibody Ibritumomab, covalently linked to the chelator Tiuxetan, enabling the incorporation of the short-lived β-emitter radioisotope yttrium-90. It is utilized in the research of non-Hodgkin's B-cell lymphomas [1] [2].

Ibritumomab和Tiuxetan通过共价硫脲键结合。Tiuxetan为两种放射性物质Indium-111 (In-111)和Yttrium-90 (Y-90)提供了一个限制螯合位点。